There's a lot for investors to talk about.

In a world where healthcare innovation is accelerating, companies leveraging artificial intelligence are leading the charge in transforming patient care, diagnostics, and therapeutic solutions. Their advancements in smart disinfection, AI-designed therapies, precision gene editing, and cardiovascular diagnostics are not only reshaping their industries but also unlocking tremendous growth potential. Here's how these cutting-edge companies are redefining the future of healthcare.

MGX-001 in Hemophilia A Advances Towards US and Ex-US Regulatory Interactions in 2025

EMERYVILLE, Calif., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced that Eric Bjerkholt, MBA, CFO of Mirum Pharmaceuticals, Inc., will join Metagenomi’s Board of Directors, serving on Metagenomi’s Audit and Compensation committees, effective January 27, 2025.

EMERYVILLE, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced that Brian C. Thomas, PhD, CEO and founder of Metagenomi, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 4:30 p.m. PT in San Francisco.

MGX-001, utilizing a highly specific and efficient MG29-1 nuclease, exhibits no identifiable off-target editing

Therapeutically relevant levels of Factor VIII (FVIII) activity sustained in ongoing nonhuman primate (NHP) study through more than sixteen months of follow up

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Metagenomi, Inc. (“Metagenomi” or the “Company”) (NASDAQMGX) and reminds investors of the November 25, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of all purchasers of stock of Metagenomi, Inc. (NASDAQMGX) pursuant and/or traceable to the Company’s initial public offering conducted between February 9 and 13, 2024 (the “IPO”). Metagenomi describes itself as a “genetics medicine company.”

The Law Offices of Frank R. Cruz reminds investors of the upcoming November 25, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Metagenomi, Inc. (“Metagenomi” or the “Company”) (NASDAQMGX) securities pursuant and/or traceable to the Company’s February 2024 initial public offering (the “IPO”).

PHILADELPHIA, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Metagenomi Inc. (“Metagenomi” or the “Company”) (NASDAQMGX) on behalf of purchasers of Metagenomi securities between February 6, 2024 and September 26, 2024, inclusive (the “Class Period”).

NEW YORK, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:

NEW YORK, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Metagenomi, Inc. (“Metagenomi” or the “Company”) (NASDAQMGX) in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased or otherwise acquired Metagenomi securities pursuant and/or traceable to Metagenomi's registration statement for the initial public offering held between February 9, 2024, and May 1, 2024, both dates inclusive (the “Class Period”). Investors have until November 25, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Metagenomi To Contact Him Directly To Discuss Their Options

PHILADELPHIA, Nov. 18, 2024 (GLOBE NEWSWIRE) -- A securities class action lawsuit has been filed against Metagenomi Inc. (“Metagenomi” or the “Company”) (NASDAQMGX). The lawsuit has been filed on behalf of purchasers of Metagenomi securities between February 6, 2024 and September 26, 2024, inclusive (the “Class Period”).

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Metagenomi To Contact Him Directly To Discuss Their Options

Initiating IND-enabling activities for MGX-001 development candidate (DC) in hemophilia A; Achieved durable Factor VIII activity levels over twelve months in nonhuman primate (NHP) study

NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) --

PHILADELPHIA, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Metagenomi Inc. (“Metagenomi” or the “Company”) (NASDAQMGX) on behalf of purchasers of Metagenomi securities between February 6, 2024 and September 26, 2024, inclusive (the “Class Period”).

NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP:

NEW YORK, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Metagenomi, Inc. (“Metagenomi” or the “Company”) (NASDAQMGX) in the United States District Court for the Northern District of California on behalf of all persons and entities who purchased or otherwise acquired Metagenomi securities pursuant and/or traceable to Metagenomi's registration statement for the initial public offering held between February 9, 2024, and May 1, 2024, both dates inclusive (the “Class Period”). Investors have until November 25, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.